Medisprof S.R.L.

Az itteni vizsgálatok

Miről szól a helyszín 46 vizsgálata, a regiszteri adatlapjaik szerint.

Betegségek

• Tüdőrák27 vizsgálat
• Gyomor- és nyelőcsőrák4 vizsgálat
• Melanóma4 vizsgálat
• Áttétes emlőrák3 vizsgálat
• Fej-nyaki daganatok3 vizsgálat
• Petefészekrák2 vizsgálat
• Vesedaganat2 vizsgálat
• Gyermekkori daganatok1 vizsgálat
• Hasnyálmirigyrák1 vizsgálat
• Pajzsmirigyrák1 vizsgálat
• Prosztatarák1 vizsgálat
• Tripla negatív emlőrák1 vizsgálat
• és még 1

Fázis

• 3. fázis34 vizsgálat
• 2. fázis6 vizsgálat
• 2/3. fázis5 vizsgálat
• 4. fázis1 vizsgálat

Állapot

• Lezárult21 vizsgálat
• Fut, nem toboroz12 vizsgálat
• Toboroz11 vizsgálat
• Még nem toboroz2 vizsgálat

Fő szponzor

• Amgen4 vizsgálat
• AstraZeneca3 vizsgálat
• H e x a l AG3 vizsgálat
• Mirati Therapeutics Inc.3 vizsgálat
• Regeneron Pharmaceuticals3 vizsgálat
• és még 27

Futó vizsgálatok

• Toboroz

  A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

  NCT07365319· 2/3. fázis· Eikon Therapeutics· Forrás

• Toboroz

  A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

  NCT06908304· 3. fázis· Maia Biotechnology· Forrás

• Toboroz

  Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

  NCT07085767· 3. fázis· Olema Pharmaceuticals, Inc.· Forrás

• Toboroz

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· 3. fázis· ImmunityBio, Inc.· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Pfizer· Forrás

• Toboroz

  Trial of Trastuzumab Deruxtecan (Enhertu®) Plus Chemotherapy Plus or Minus Pembrolizumab versus Chemotherapy Plus Trastuzumab Plus or Minus Pembrolizumab in First-line Metastatic HER2-positive Gastric or GEJ Cancer

  2024-513122-27-00· 3. fázis· Daiichi Sankyo Inc.· Forrás

• Toboroz

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· 3. fázis· European Organisation for Research and Treatment of Cancer - EORTC· Forrás

• Toboroz

  A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

  NCT06901531· 3. fázis· Astellas Pharma Global Development, Inc.· Forrás

• Toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  NCT06767514· 3. fázis· Summit Therapeutics· Forrás

• Toboroz

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· 2/3. fázis· BioNTech SE· Forrás

• Fut, nem toboroz

  A study to continue providing GME751 (a new medicine that is similar to pembrolizumab) to participants who are eligible for pembrolizumab treatment after participation in previous studies (CGME751A12101 or CGME751A12301)

  2024-513160-25-00· 3. fázis· H e x a l AG· Forrás

• Fut, nem toboroz

  Volrustomig Priming Regimens Exploratory Phase II Platform Study

  NCT06448754· 2. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy

  2023-508359-38-00· 3. fázis· Amgen Inc.· Forrás

• Fut, nem toboroz

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás

• Fut, nem toboroz

  A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma

  2023-503288-40-00· 3. fázis· Amgen Inc.· Forrás

• Toboroz

  A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

  NCT06064877· 3. fázis· AVEO Pharmaceuticals, Inc.· Forrás

• Fut, nem toboroz

  REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

  NCT05973773· 3. fázis· Taiho Oncology, Inc.· Forrás

• Toboroz

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

  NCT05382299· 3. fázis· Gilead Sciences· Forrás

• Fut, nem toboroz

  Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

  NCT05352672· 3. fázis· Regeneron Pharmaceuticals· Forrás

• Fut, nem toboroz

  THIO Sequenced With Cemiplimab in Advanced NSCLC

  NCT05208944· 2. fázis· Maia Biotechnology· Forrás

• Toboroz

  Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás

• Fut, nem toboroz

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer

  NCT03937154· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· 3. fázis· Tesaro, Inc.· Forrás

• Fut, nem toboroz

  A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

  NCT01896479· 4. fázis· Exelixis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák9 toboroz
• Áttétes emlőrák1 toboroz
• Fej-nyaki daganatok1 toboroz
• Gyomor- és nyelőcsőrák1 toboroz
• Prosztatarák1 toboroz

Lezárt vizsgálatok

• Lezárult

  Integrated PK/efficacy, safety, and immunogenicity study to demonstrate similarity of JPB898, a proposed biosimilar to nivolumab, to Opdivo® in combination with Yervoy®

  NCT06587451· 3. fázis· H e x a l AG· Forrás

• Toboroz

  A Randomized, Double-Blind, Placebo-Controlled, MultiRegional Phase III Clinical Study of Toripalimab Alone or in Combination With Tifcemalimab (JS004/TAB004) as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Disease Progression Following Chemoradiotherapy

  2023-507097-41-01· 3. fázis· Shanghai Junshi Biosciences Co. Ltd.· Forrás

• Lezárult

  A study to compare efficacy, safety, and immune response of GME751 and EU-authorized Keytruda in adult participants with untreated metastatic lung cancer

  2023-506882-70-00· 3. fázis· H e x a l AG· Forrás

• Fut, nem toboroz

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· 2. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  A trial to show the similarity in effects, safety and immune response of FYB206 compared to Keytruda in people with metastatic non-squamous non-small cell lung cancer (NSCLC)

  2023-509766-37-00· 3. fázis· Formycon AG· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· F. Hoffmann-La Roche AG· Forrás

• Fut, nem toboroz

  Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06082167· 2/3. fázis· Exelixis· Forrás

• Lezárult

  APRILIAH (Aprogen Phase III Clinical Trial to Compare Efficacy, Safety, and Immunogenicity of AP063 in Subjects with HER2+ Breast Cancer)

  2023-506975-83-00· 3. fázis· Aprogen Inc.· Forrás

• Lezárult

  A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC

  2022-503007-22-00· 2. fázis· Bristol-Myers Squibb Services Unlimited Company· Forrás

• Fut, nem toboroz

  Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

  NCT05853575· 2. fázis· Mirati Therapeutics Inc.· Forrás

• Toboroz

  Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

  NCT05718323· 2. fázis· ETOP IBCSG Partners Foundation· Forrás

• Fut, nem toboroz

  A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT05785767· 2/3. fázis· Regeneron Pharmaceuticals· Forrás

• Lezárult

  Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN High Risk, Cisplatin-ineligible Participants (XRAY VISION)

  2023-508528-36-00· 3. fázis· Merck Healthcare KGaA· Forrás

• Lezárult

  A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body

  NCT05568095· 3. fázis· Arcus Biosciences, Inc.· Forrás

• Fut, nem toboroz

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· 3. fázis· AstraZeneca· Forrás

• Lezárult

  Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

  NCT05153239· 3. fázis· PharmaMar· Forrás

• Lezárult

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· 3. fázis· Amgen· Forrás

• Fut, nem toboroz

  Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

  NCT05043090· 3. fázis· AstraZeneca· Forrás

• Fut, nem toboroz

  A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

  NCT04810078· 3. fázis· Bristol-Myers Squibb· Forrás

• Fut, nem toboroz

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· 3. fázis· Mirati Therapeutics Inc.· Forrás

• Lezárult

  Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer

  NCT03362177· 3. fázis· Amgen· Forrás